Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda; Mark Sausen; Rebecca J. Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R. Bartlett; Hao Wang; Brandon Luber; Rhoda M. Alani; Emmanuel S. Antonarakis; Nilofer S. Azad; Alberto Bardelli; Henry Brem; John L. Cameron; Clarence C. Lee; Leslie A. Fecher; Gary L. Gallia; Peter Gibbs; Dung Le; Robert L. Giuntoli; Michael Goggins; Michael D. Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H. Juhl; Jenny J. Kim; Giulia Siravegna; Daniel A. Laheru; Calogero Lauricella; Michael Lim; Evan J. Lipson; Suely Kazue Nagahashi Marie; George J. Netto; Kelly S. Oliner; Alessandro Olivi; Louise Olsson; Gregory J. Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T. Harkins; Silvio Veronese; Tian-Li Wang; Jon D. Weingart; Christopher L. Wolfgang; Laura D. Wood; Dongmei Xing; Ralph H. Hruban; Jian Wu; Peter J. Allen; C. Max Schmidt; Michael A. Choti; Victor E. Velculescu; Kenneth W. Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A. Diaz

doi:10.1126/scitranslmed.3007094

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Submit a Response to This Article

Compose eLetter

Title

Author Information

Contributors
First name and middle name First or given name, e.g. 'Peter'. Last Name Your last, or family, name, e.g. 'MacMoody'. Email Your email address, e.g. higgs-boson@gmail.com Role / Occupation Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests?

Yes

Please describe the competing interests

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

No eLetters have been published for this article.

View Full Text

Science Translational Medicine

Vol 6, Issue 224
19 February 2014

Table of Contents

Article Tools

Email

Thank you for your interest in spreading the word about Science Translational Medicine.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email

Your Name

Send To
Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

Your Personal Message

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Powerpoint
Print
Alerts

Please log in to add an alert for this article.

Log In with your AAAS ID

Sign In to Email Alerts with your Email Address
Email
Citation tools
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

By Chetan Bettegowda, Mark Sausen, Rebecca J. Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R. Bartlett, Hao Wang, Brandon Luber, Rhoda M. Alani, Emmanuel S. Antonarakis, Nilofer S. Azad, Alberto Bardelli, Henry Brem, John L. Cameron, Clarence C. Lee, Leslie A. Fecher, Gary L. Gallia, Peter Gibbs, Dung Le, Robert L. Giuntoli, Michael Goggins, Michael D. Hogarty, Matthias Holdhoff, Seung-Mo Hong, Yuchen Jiao, Hartmut H. Juhl, Jenny J. Kim, Giulia Siravegna, Daniel A. Laheru, Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore-Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba-Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian-Li Wang, Jon D. Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Diaz, Jr

Science Translational Medicine19 Feb 2014 : 224ra24

Circulating tumor DNA can be used in a variety of clinical and investigational settings across tumor types and stages for screening, diagnosis, and identifying mutations responsible for therapeutic response and drug resistance.

Supplementary Materials

Citation Manager Formats

BibTeX

Bookends

EasyBib

EndNote (tagged)

EndNote 8 (xml)

Medlars

Mendeley

Papers

RefWorks Tagged

Ref Manager

RIS

Zotero
Share
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

By Chetan Bettegowda, Mark Sausen, Rebecca J. Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R. Bartlett, Hao Wang, Brandon Luber, Rhoda M. Alani, Emmanuel S. Antonarakis, Nilofer S. Azad, Alberto Bardelli, Henry Brem, John L. Cameron, Clarence C. Lee, Leslie A. Fecher, Gary L. Gallia, Peter Gibbs, Dung Le, Robert L. Giuntoli, Michael Goggins, Michael D. Hogarty, Matthias Holdhoff, Seung-Mo Hong, Yuchen Jiao, Hartmut H. Juhl, Jenny J. Kim, Giulia Siravegna, Daniel A. Laheru, Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore-Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba-Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian-Li Wang, Jon D. Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Diaz, Jr

Science Translational Medicine19 Feb 2014 : 224ra24

Circulating tumor DNA can be used in a variety of clinical and investigational settings across tumor types and stages for screening, diagnosis, and identifying mutations responsible for therapeutic response and drug resistance.

Supplementary Materials
Share This Article: